Vor Biopharma (NYSE:VOR) Trading Down 2.9% - What's Next?

Key Points

• Vor Biopharma's stock price fell by 2.9% to $2.35, with a trading volume of approximately 6.5 million shares, significantly lower than its average daily volume.
• HC Wainwright upgraded Vor's rating from "neutral" to "buy", with a target price of $3.00, while other analysts varied in their assessments, resulting in a current consensus rating of "Moderate Buy".
• Institutional investors hold 97.29% of Vor Biopharma's stock, with significant stakes acquired by RA Capital Management and other hedge funds in recent quarters.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report)'s share price dropped 2.9% during trading on Tuesday . The company traded as low as $2.30 and last traded at $2.35. Approximately 6,526,475 shares traded hands during mid-day trading, a decline of 21% from the average daily volume of 8,310,444 shares. The stock had previously closed at $2.42.

Analyst Upgrades and Downgrades

VOR has been the subject of a number of recent research reports. Baird R W downgraded shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Jones Trading downgraded shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. HC Wainwright upgraded shares of Vor Biopharma from a "neutral" rating to a "buy" rating and set a $3.00 target price for the company in a report on Monday, June 30th. Finally, JMP Securities reiterated a "market perform" rating and issued a $6.00 target price on shares of Vor Biopharma in a report on Friday, May 9th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, Vor Biopharma presently has a consensus rating of "Moderate Buy" and an average target price of $5.63.

Vor Biopharma Stock Up 1.4%

The firm has a market cap of $262.42 million, a PE ratio of -1.27 and a beta of 2.04. The stock has a 50 day moving average price of $1.22 and a two-hundred day moving average price of $1.00.

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently modified their holdings of VOR. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma during the fourth quarter worth about $80,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of Vor Biopharma during the fourth quarter worth about $33,000. Lynx1 Capital Management LP purchased a new stake in shares of Vor Biopharma during the fourth quarter worth about $707,000. Northern Trust Corp grew its stake in shares of Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after acquiring an additional 44,252 shares during the last quarter. Finally, RA Capital Management L.P. grew its stake in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after acquiring an additional 16,897,159 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.